Opinion
Video
Author(s):
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The discussion focuses on adverse effects with B-cell maturation antigen (BCMA)–targeted bispecific antibodies. Cytokine release syndrome (CRS) from immune activation is common, manifesting as flu-like fever, tachycardia, hypotension, or hypoxemia, but high-grade CRS is rare. Neurotoxicity can also occur, usually low grade manifesting as headaches or sensory changes, but more severe immune effector cell–associated neurotoxicity syndrome is possible. Careful monitoring, especially early during step-up dosing, is imperative.
A major late effect is immunosuppression and infections. Intravenous immunoglobulin replacement is routinely used given profound B-cell aplasia. Prophylactic antibiotics or antivirals can be considered, but aggressively evaluating and treating suspected infections is critical. Myeloma patients are already immunocompromised at baseline from prior therapies, so infections require prompt evaluation and treatment in this population. Establishing relationships with infectious disease specialists is advised to help comanage infections with these novel immunotherapies.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
2 Commerce Drive
Cranbury, NJ 08512